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Abstract
Recent epidemiologic data linking proton pump inhibitor (PPI) use to acute and chronic kidney 
dysfunction is yet to be validated in other populations, and mechanisms have not been explored. 
Using a large, well phenotyped inception cohort of 15,063 critically ill patients, we examined the 
risk of acute kidney injury (AKI), as defined by the Kidney Disease Improving Global Outcomes 
criteria guidelines, according to prior use of a PPI, histamine-2 receptor antagonist (H2RA), or 
neither. A total of 3,725(24.7%) patients reported PPI use prior to admission, while 905(6.0%) 
patients reported H2RA use. AKI occurred in 747(20.0%) and 163(18.0%) of PPI and H2RA users 
respectively, compared to 1,712(16.2%) of those not taking acid suppressive medications. In 
unadjusted analysis, PPI and H2RA users had a 28% (95% CI 1.17–1.41, p<0.001) and 10% (95% 
CI 0.91–1.30, p=0.31) higher risk of AKI compared to those taking neither class of medication. 
However, in sequential models that included adjustment for demographics, cardiovascular 
comorbidities, indications for PPI use, and severity of illness, the effect of PPI on the risk of AKI 
was attenuated, and in the adjusted analysis, PPI was not associated with AKI (OR 1.02; 95% CI 
0.91–1.13, p=0.73). The presence of sterile pyuria and hypomagnesemia did not modify the 
association between PPI use and AKI. In summary, after adjustment for demographics, illness 
severity and the indication for PPI use, PPI use prior to admission is not associated with critical 
illness AKI.
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Introduction
Recent epidemiologic data suggests that proton pump inhibitor (PPI) use may be associated 
with an increased risk of acute and chronic kidney disease, adding to a list of accumulating 
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potential risks, including hypomagnesemia(1), infection(2), cardiovascular disease(3, 4), and 
mortality(5). Using the Atherosclerosis Risk in Communities study, a prospective 
observational study of representative communities, Lazarus et al. have linked self-reported 
PPI use to the development of chronic kidney disease (CKD), and then replicated the 
findings using a large hospital electronic medical record(6). PPI use has also been associated 
with an increased risk of acute kidney injury (AKI)(7, 8).
Mechanisms for this observed association have not previously been explored, but might 
occur through episodes of acute interstitial nephritis (AIN), a known PPI associated adverse 
effect (9–12). Although there are no standard diagnostic criteria for AIN, signs of non-
infectious inflammation, such as sterile pyuria and white cell casts, along with 
eosinophiluria, are frequently used as clinical indicators. In addition, data has suggested that 
PPI exposure might lead to endothelial dysfunction and vasoconstriction, presumably 
through impaired lysosomal function(13) and decreased nitrogen oxide levels(14) 
respectively, and might explain the observed association between PPI use and myocardial 
infarction(15) and dementia(16). These findings might similarly link PPI use to AKI(17). 
And finally, hypomagnesemia, a potential consequence of chronic PPI use(1, 18), has been 
associated with an increased risk of chronic renal disease progression(19, 20).
Hypothesizing that PPI use might increase susceptibility to AKI, particularly in patients 
exposed to the physiologic stressors of critical illness, we examined whether PPI use prior to 
hospitalization was associated with an increased risk of AKI within the first seven days of 
critical illness. In addition, to explore potential mechanisms linking PPI use and AKI, we 
examined whether the presence of sterile pyuria, a clinical indicator of interstitial nephritis, 
and hypomagnesemia, modified the association of PPI use and AKI.
METHODS
Study Population
We used the MIMIC-II (Multiparameter Intelligent Monitoring in Intensive Care) research 
database, a joint venture managed by researchers from the Laboratory for Computational 
Physiology at Massachusetts Institute of Technology (MIT) and the Department of Medicine 
at the Beth Israel Deaconess Medical Center (BIDMC). BIDMC is a large, urban academic 
medical center. The database contains lab results, electronic documentation, and bedside 
monitor trends and waveforms for all patients admitted to a BIDMC intensive care unit 
(ICU) between 2001 and 2008. Use of the MIMIC II database has been approved by the 
Institutional Review Boards of BIDMC and MIT. MIMIC-II contains data from 24,581 adult 
patients who were admitted to surgical or medical ICUs at BIDMC. Of the 16,192 with 
documented admission medication lists, and after excluding patients with End Stage Renal 
Disease and those missing documentation of renal function, a cohort analysis of 15,063 
unique first hospitalizations remained.
Primary medication exposure
PPI or H2RA exposure was defined as any PPI or H2RA listed as a pre-admission 
medication. We developed a Natural Language Processing (NLP) algorithm that searched 
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discharge summaries for a discrete home medication section within the History and Physical 
examination performed on admission, as previously described(1).
Primary Outcome
The primary outcome was AKI during the first 7 days of ICU care, as defined by either a 
≥0.3 mg/dL creatinine increase within 48 hours of admission or a ≥50 percent increase 
within 7 days of admission, or acute dialysis, in keeping with the Kidney Disease Improving 
Global Outcomes (KDIGO) guidelines. Admission creatinine was used to determine 
“baseline” renal function in keeping with best practice guidelines(21). In addition, we 
explored the association of PPI use with AKI as determined by a urine output of <0.5 
mL/kg/hour for more than 6 hours during the first seven days of critical illness, in keeping 
with an alternative KDIGO definition.
Covariates
Demographic information included age, sex, and ethnicity, coded as White, African-
American, Asian, Hispanic, Other, or Unknown, and ICU type (medical, surgical, or 
cardiac). We used oral diabetes medication or insulin usage as identified in admission 
medication lists, along with Elixhauser discharge coding, to identify diabetic patients(22). 
We identified heart failure patients through NLP searching of the past medical history 
section of the admission examination or Elixhauser discharge coding. A history of cardiac 
arrhythmia, pulmonary circulation disorder, hypertension, liver disease, peptic ulcer disease, 
alcohol abuse, weight loss, obesity and metastatic cancer were included according to 
Elixhauser discharge coding. Admission ICU vitals included systolic and diastolic blood 
pressure and heart rate. Age, sex, and race were used to impute missing vitals in 733 
patients. Laboratory values obtained within 24 hours of ICU admission included white blood 
cell and platelet counts, and glucose and hemoglobin concentrations. We used a NLP 
algorithm of admission medication lists to document angiotensin receptor blocker (ARB), 
angiotensin converting enzyme inhibitor (ACE-I), diuretic and statin usage.
Statistical analysis
We present baseline characteristics according to use of PPI, H2RA, or neither, with p values 
calculated for group differences between PPI and H2RA users. We used logistic regression 
to describe the association of PPI use with AKI. To explore the potential effect of residual 
confounding, we performed sequential regressions with incremental adjustments, with 
variables chosen based on clinical judgment. We created indicator variables for PPI use and 
H2RA use. Model 1 included age, sex, and race. Model 2 included model 1 plus admission 
intensive care unit type, history of diabetes, congestive heart failure, cardiac arrhythmia, 
hypertension or pulmonary circulation disorder. Model 3 included model 2 plus a history 
liver disease, peptic ulcer disease, alcohol abuse, weight loss, obesity and metastatic cancer. 
Model 4 included Model 3 plus admission systolic blood pressure, diastolic blood pressure, 
heart rate, glucose, white blood cell count, hemoglobin, and platelet count. Model 5 included 
Model 4 plus use of diuretics, ace inhibitor, angiotensin receptor blocker, and statins. All 
models included PPI and H2RA, and the reference category was therefore patients not taking 
acid suppression medications. In addition, we included admission serum creatinine in Model 
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5, and used backwards stepwise regression to identify the significant (p values <0.001) 
predictors of AKI.
In absence of standard clinical criteria to identify sterile pyuria, we a priori considered the 
presence of urinary white cells, without either genitourinary contamination or infection, as 
indicative of potential renal tubulointerstitial inflammation. 6,174 patients had a urinalysis 
completed within 12 hours of ICU admission. We excluded patients with a positive urine 
culture (n=688), greater than two epithelial cells per high powered field (hpf)(n=551), 
bacteruria [few(n=803), rare (n=480), occasional (n=621), moderate (n=290), many (n=223) 
and loaded (n=1)] or with positive nitrate on urine dipstick (n=21), leaving 2,657 patients 
with documented urine dipstick analyses and 1,366 patients with documented urinary 
microscopy. Among these, sterile pyuria was defined as the presence of leukocyte esterase 
on urine dipstick, or greater than five white blood cells (WBC)s/hpf on urine microscopy, in 
keeping with our hospital laboratory’s definition. We created indicator variables for those 
PPI users with sterile pyuria and PPI users without sterile pyuria, and were regressed into 
Model 5 above.
To examine whether hypomagnesemia modified the association between PPI use and risk of 
AKI, we examined a multiplicative interaction term between PPI and a serum magnesium 
concentration of <1.6 mg/dl, in keeping with our hospital laboratory definition of 
hypomagnesemia, in 10,868 patients with magnesium concentrations measured within 24 
hours of ICU admission.
Finally, in order to explore whether PPI use was indicating general illness severity (model 
specificity), we examined the association of pre-morbid PPI use with the risk of sepsis, as 
determined by Martin criteria(23), in adjusted analysis (Model 5), an outcome seemingly 
unlikely to be physiologically linked to PPI use. All analyses were performed using JMP Pro 
12 (SAS Institute, Cary, NC).
Results
Baseline Characteristics
Of 15,063 critically ill patients, 3,725(24.7%) and 905(6.0%) were using a PPI or H2RA, 
respectively, prior to admission. PPI users tended to be older and generally sicker than those 
not taking acid suppression, with a higher prevalence of most comorbidities, including 
diabetes, heart disease, liver failure, and more frequent use of diuretics, ACE-Is, and ARB’s 
(Table I). Compared to H2RA users, those taking PPIs had a higher prevalence of liver 
disease, alcohol abuse, and diuretic use, a lower admission hemoglobin and a higher 
admission serum creatinine.
PPI use and AKI risk
AKI occurred in 747(20%) and 163(18%) of PPI and H2RA users, respectively, compared to 
1,712(16%) in those patients not taking an acid suppression medication. While the 
unadjusted risk of AKI with PPI use was significantly higher than those without acid 
suppression medication usage (Table II), adjustment for demographics (Model 1) and 
traditional cardiovascular comorbidities (Model 2) attenuated the association, although it 
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remained significant. However, the inclusion of standard clinical indications for PPI usage 
further attenuated the association (Model 3). In the final adjusted model (Model 5), PPI use 
was not significantly associated with a risk of AKI.
In Model 5, the significant predictors of AKI (p value <0.05) were age, sex, ICU type, 
history of diabetes, heart failure, hypertension, obesity, weight loss, liver disease, systolic 
blood pressure and heart rate, all four laboratory parameters, diuretic, statin, and ARB use. 
Inclusion of admission serum creatinine in Model 5 had little effect on the association of PPI 
and AKI(OR 1.02; 95% CI 0.91–1.28 p=0.77). In a model that used backwards stepwise 
regression to identify the significant predictors of AKI, PPI use was similarly not associated 
with AKI (OR 1.04; 95% CI 0.94–1.16, p=0.41).
In 11,312 patients with documented urinary output, PPI use was similarly not associated 
with an adjusted risk of AKI (p=0.41), as defined by urinary output.
PPI use, sterile pyuria, and AKI
There were 634(24%) and 148(6%) PPI and H2RA users respectively in those with 
documented urine dipstick analyses within 12 hours of ICU admission, and 323(24%) and 
89(7%) PPI and H2RA users in those with documented urinary microanalyses. Compared to 
patients taking no acid suppression, PPI users with sterile pyuria, defined by either leukocyte 
esterase positivity or >5 WBC’s/hpf, did not have a significantly higher risk of AKI in 
adjusted analysis (Table III).
PPI users with leukocyte positivity and >5 WBC’s/hpf did not have a significantly higher 
adjusted risk of AKI compared to PPI users without sterile pyuria (OR 1.02; 95% CI 0.44–
2.16, p=0.96 and OR 1.38; 0.52–3.42,p=0.49, respectively).
PPI use and AKI risk in hypomagnesemia
There were 1,704 (16%) patients with hypomagnesemia on ICU admission. A multiplicative 
interaction term between PPI use and hypomagnesemia was not significant (p=0.75). 
Amongst those with hypomagnesemia, PPI use was not associated with a significantly 
increased risk of AKI (OR 1.04, 95% CI 0.76–1.41, p=0.80).
Model control
There were 1,539 (10%) admissions for sepsis. Despite adjustment for demographics, 
multiple comorbidities and illness severity (Model 5), premorbid PPI use remained 
significantly associated with the risk of sepsis (OR 1.22 95% CI 1.07–1.39, p=0.003), 
suggesting that our model continued to lack specificity.
Discussion
Our data suggests that PPI use is not associated with an increased risk of AKI in critically ill 
patients, and highlights the potential challenge of residual confounding in observational 
studies.
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Our negative findings might potentially be explained by study differences. Whereas the 
Lazarus study was conducted longitudinally in a community and an outpatient setting, our 
cross sectional analysis was restricted to the critically ill. Given the increased incidence of 
AKI in critical illness, with almost 17% of ICU admissions complicated by AKI within the 
first seven days, it is plausible that any potential effect of PPI use on the risk of kidney injury 
is dwarfed by the complex additional influences that might lead to renal injury in critical 
illness.
However, our analysis also raises important questions about the limitations of observational 
data in determining causality, and highlight potential sources of bias and residual 
confounding. Most previous studies, including our own, could not accurately identify the 
reason for PPI prescription. We used discharge coding to identify the comorbidities that 
might warrant PPI use, likely leading to significant misclassification. However, despite this 
limitation, inclusion of these comorbidities into our modelling (Model 4) attenuated the 
association of PPI use with AKI. For example, 8% of PPI users had liver disease by 
discharge coding, which was associated with a 33% increased risk of AKI. Since liver 
disease is an independent risk for kidney failure, yet its consequences, such as variceal 
bleeding, are an indication for PPI use(24), significant confounding by indication likely 
remains.
One approach to this has been to use H2RA users as a model control. However, the decision 
of a physician to prescribe a PPI, which is generally more expensive, with a greater overall 
adverse risk profile, and typically used in the setting of H2RA failure, does not equate the 
decision to prescribe a H2RA. In our analysis, PPI users were clearly “sicker” than both 
H2RA users and those using neither class of medicines, with a higher prevalence of 
comorbidities such as liver disease, lower admission serum hemoglobin concentrations, and 
more frequent use of medications that are associated with renal injury, such as diuretics. 
Although many of these factors can be entered into “adjusted analyses”, accurately adjusting 
for the powerful and complex biologic effects of these conditions on an outcome is likely a 
statistical simplification than does not reflect the physiologic reality. Furthermore, despite 
our best efforts of “adjustment”, including a wide range of patient characteristics, PPI use 
remained significantly associated with an admission for sepsis, an outcome that lack’s 
obvious physiologic explanation, suggesting that PPI use might simply mark disease 
severity.
Since the proposed mechanism between PPI use and adverse renal outcomes could be 
through interstitial nephritis, we examined the effect of sterile pyuria on the association of 
PPI and AKI. But, we found that PPI users with sterile pyuria did not have a higher risk of 
AKI than those not taking acid suppression medicines nor than PPI users without sterile 
pyuria. In addition, we could not detect a significant association between PPI use and AKI in 
those with hypomagnesemia.
The strengths of our analysis lies in the granularity or the MIMIC dataset, providing access 
to discharge summaries, medications, laboratory parameters, as well as comorbidities, 
thereby allowing accurate determination of both the primary outcome and exposure. The use 
of sequential models illustrates the effect of residual confounding in our observational 
Lee et al. Page 6
J Clin Pharmacol. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
analysis. There are several limitations of our analysis. Restricted to critically ill patients, our 
negative results cannot be extrapolated to a broader context without further study. In 
addition, we could not quantify the amount of PPI exposure, nor account for over-the-
counter PPI use, and thus misclassification is possible. Furthermore, although we 
hypothesized that sterile pyuria is indicative of an interstitial nephritis, direct examination of 
a spun urine sediment for white cell casts is likely a superior diagnostic method, but was not 
available.
Conclusion
In summary, in adjusted analysis that includes some indication for PPI prescription, PPI use 
is not associated with AKI in critically ill patients. Despite recent suggestions otherwise, the 
association between PPI and renal outcomes remains hypothesis generating, and requires 
more rigorous analysis that limits residual confounding.
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Table I
Baseline characteristics according to acid suppression use
Proton-pump inhibitors (n=3,725) H2-receptor antagonists (n=905)
No acid-
suppressive 
medications 
(n=10,528)
P value1
Age, mean (SD), y 67.9 (15.1) 67.4 (15.3) 61.8 (19.7) .75
Male, no. (%) 2017 (54.1) 497 (55.1) 6143 (58.0) 0.23
Ethnicity, no. (%)
White 2750 (73.4) 659 (72.8) 7455 (70.8)
0.68
Black or African American 285 (7.6) 69 (7.6) 747 (7.1)
Hispanic or Latino 101 (2.7) 24 (2.8) 343 (3.2)
Asian 64 (1.7) 17 (1.8) 258 (2.5)
Other 68 (1.8) 15 (1.7) 287 (2.7)
Unknown 457 (12.2) 121 (13.4) 1438 (13.7)
Past Medical History, no. (%)
Hypertension 1396 (37.5) 320 (35.3) 3593 (34.1) 0.16
Diabetes 1293 (34.7) 308 (34.0) 2576 (24.5) 0.86
Congestive Heart Failure 1103 (29.6) 253 (28.0) 2069 (19.7) 0.46
Cardiac arrhythmia 882 (23.7) 202 (22.3) 1893 (18.0) 0.48
Liver disease 307 (8.2) 47 (5.2) 417 (4.0) 0.003
Obesity 82 (2.2) 14 (1.5) 201 (1.9) 0.05
Metastatic cancer 196 (5.2) 47 (5.2) 465 (4.4) 0.91
Alcohol abuse 180 (4.8) 30 (3.3) 652 (6.2) 0.04
Weight loss 117 (3.1) 18 (2.0) 178 (1.7) 0.09
Peptic ulcer disease 40 (0.1) 8 (0.1) 54 (0.1) 0.37
Vital signs, mean (SD)
Systolic blood pressure, mmHg 125.1 (25.3) 125.2 (25.9) 125.8 (24.2) 0.72
Diastolic blood pressure, mmHg 62.4 (15.6) 62.5 (15.6) 64.3 (15.5) 0.92
Heart rate, beats/min 88.0 (19.6) 86.7 (18.9) 87.7 (19.3) 0.08
Laboratory values on admission, mean (SD)
Glucose, mg/dL 149.4 (84.3) 150.2 (88.1) 150.5 (91.9) 0.89
Hemoglobin, g/dL 11.4 (2.2) 11.8 (2.1) 12.2 (2.2) <0.001
White blood cell count, K/uL 11.9 (7.4) 12.2 (8.0) 12.3 (9.5) 0.19
Platelets, K/uL 236.7 (125.7) 240.2 (113.6) 235.2 (111.1) 0.69
Albumin, g/dL2 3.3 (0.7) 3.4 (0.6) 3.5 (0.7) 0.27
Creatinine, mg/dL 1.5 (1.4) 1.3 (1.1) 1.2 (1.2) 0.002
Pre-illness medication usage no. (%)
Angiotensin Conv. Enzyme 
Inhibitor 1044 (29.8) 253 (29.8) 2382 (22.6) 0.97
Angiotensin Receptor Blocker 309 (8.8) 76 (8.9) 647 (6.1) 0.99
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Proton-pump inhibitors (n=3,725) H2-receptor antagonists (n=905)
No acid-
suppressive 
medications 
(n=10,528)
P value1
Statin 1403 (40.0) 328 (38.7) 3055 (29.0) 0.37
Diuretic 1390 (39.6) 282 (33.3) 2456 (23.3) <0.001
95 individuals were taking both a PPI and H2RA
1p value represents group difference between PPI and H2RA users (excluding the 95 using both)
2Admission serum albumin concentration available in 5,828 patients.
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Table II
Association of Proton Pump Inhibitor Use with subsequent Risk of Acute Kidney Injury
Model Odds Ratio (95% confidence interval), p value
No acid suppressive 
medications Proton Pump Inhibitors Histamine Receptor Antagonists
Unadjusted
Ref.
1.28
1.17–1.41
p<0.001
1.10
0.91–1.30
p=0.31
Adjusted
Model 1. Demographics Ref.
1.20
1.08–1.31
p<0.001
1.03
0.85–1.22
p=0.78
Model 2. Model 1+ cardiovascular 
comorbidities Ref.
1.14
1.03–1.25
p=0.01
0.98
0.82–1.17
p=0.86
Model 3. Model 2 + possible clinical 
indications for PPI use Ref.
1.10
1.00–1.21
p=0.05
0.98
0.81–1.17
p=0.80
Model 4. Model 3 + severity of illness Ref.
1.04
0.94–1.15
p=0.46
0.94
0.78–1.14
p=0.57
Model 5. Model 4 + outpatient medication use Ref.
1.02
0.91–1.13
p=0.73
0.94
0.78–1.15
p=0.59
Model 1. Adjusted for age, sex, race (n=15,044)
Model 2 Adjusted for mode 1 plus admission intensive care unit type, history of diabetes, congestive heart failure, cardiac arrhythmia, hypertension 
or pulmonary circulation. (n=15,024)
Model 3. Adjusted for model 2 plus history liver disease, peptic ulcer disease, alcohol abuse, weight loss, obesity and metastatic cancer (n=15,024)
Model 4. Adjusted for model 3 plus admission systolic blood pressure, diastolic blood pressure, heart rate, glucose, white blood cell count, 
hemoglobin, and platelet count. (n=13,305)
Model 5. Adjusted for model 4 plus use of diuretics, ace inhibitor, angiotensin receptor blocker, and statins. (n=13,209)
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Table III
Proton Pump Inhibitor Users with and without sterile pyuria and risk of AKI
Odds Ratio (95% confidence interval), p value
No acid suppressive 
medications
Proton Pump Inhibitor Use 
and sterile pyuria
Proton Pump Inhibitor 
Use without sterile pyuria Histamine Receptor Antagonist
Pyuria defined by leukocyte esterase positivity
Unadjusted
Ref
1.80
0.90–3.311
p=0.09
1.52
1.17–1.97
p<0.001
1.47
0.92–2.27
p=0.10
Adjusted1
Ref.
1.16
0.54–2.27
p=0.69
1.10
0.82–1.47
p=0.51
1.21
0.73–1.92
p=0.44
Pyuria defined by > 5 WBC’s/hpf
Unadjusted
Ref.
2.66
1.20–5.47
p=0.02
1.52
1.06–2.16
p=0.02
1.72
1.20–5.47
p=0.06
Adjusted2
Ref.
1.64
0.70–3.62
p=0.24
1.05
0.69–1.57
p=0.80
1.58
0.85–2.83
p=0.14
Both analyses adjusted per model 5.
1N=2,360 in adjusted analysis
2N=1,173 in adjusted analysis
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